Diabefarm mV Table with modif.vysv. 30mg 60 pc

$2.44

Diabefarm mV Table with modif.vysv. 30mg 60 pc

Quantity:

SKU: 01427869156 Categories: , , Tags: ,

Description

Composition
Active substance:
Gliclazide – 30 mg ;.
Excipients:
Hypromellose, microcrystalline cellulose, colloidal silicon dioxide (Aerosil), magnesium stearate.
Description:
Tablets are white to grayish-yellowish shade with a facet and Valium Valium Phillips.
Product form:
The modified-release tablets 30 mg.
10 tablets in blisters of PVC film and aluminum foil printed patent.
60 tablets in a bottle of high pressure polyethylene. 3 or 6, contour packs or vial 1 together c instruction for use in a stack of cardboard.
Contraindications
– hypersensitivity to the drug; – type 1 diabetes mellitus; – diabetic ketoacidosis, diabetic precoma, diabetic coma; – hyperosmolar coma; – severe hepatic and / or renal failure; – major surgery, extensive burns, trauma and other conditions requiring insulin therapy; – ileus, gastroparesis; – state, accompanied by malabsorption of food, the development of hypoglycemia (infectious diseases); – leucopenia; – pregnancy, breast-feeding; – Children up to age 18 years.
With caution (the need for more careful monitoring and dose selection) when administered Diabefarm® CF fever syndrome, alcoholism, and thyroid diseases (in violation of its function), the elderly.
Dosage
30 mg
Indications
Diabetes mellitus type 2 in combination with diet and moderate physical load after failure of the latter.
Interaction with other drugs
Enhance the hypoglycemic effect Diabefarma® CF angiotensin converting enzyme inhibitors (captopril, enalapril), blockers of histamine H2-receptor antagonists (cimetidine), antifungal agents (miconazole, fluconazole), non-steroidal anti-inflammatory drugs (phenylbutazone, indomethacin, diclofenac, azapropazone, oxyphenbutazone), tetracycline, fibrates (clofibrate, bezafibrate), anti-inflammatory drugs (ethionamide), salicylates, oral anticoagulants coumarin, anabolic steroids, beta-blockers, tsiklofos amide, chloramphenicol, monoamine oxidase inhibitors, sulfonamides prolonged action, fenfluramine, fluoxetine, pentoxifylline, guanethidine, theophylline, drugs that block tubular secretion, reserpine, bromocriptine, disopyramide, pyridoxine, allopurinol, ethanol and etanolsoderzhaschie preparations, as well as other hypoglycemic drugs (acarbose, biguanides, insulin).
Loosen the hypoglycemic effect Diabefarma® CF barbiturates, steroids, sympathomimetics (epinephrine, clonidine, ritodrine, salbutamol, terbutaline), phenytoin blockers “slow” calcium channels, carbonic anhydrase inhibitors (acetazolamide), thiazide diuretics, chlorthalidone, furosemide, triamtaren, asparaginase, baclofen , danazol, diazoxide, isoniazid, morphine, glucagon, rifampicin, thyroid hormones, lithium salts, in higher doses – nicotinic acid, chlorpromazine, estrogens and oral contraceptives containing them.
When interacting with ethanol development disulfiramopodobnyh reaction.
Gliclazide increases the risk of ventricular arrhythmias in patients receiving cardiac glycosides.
Beta-blockers, clonidine, reserpine, guanethidine may mask the clinical manifestations of hypoglycemia.
While the use of drugs which suppress bone marrow hematopoiesis, increased risk myelosuppression.
Overdose
In case of overdose possible hypoglycemia, until the development of hypoglycemic coma. Treatment: If the patient is conscious – to take into digestible carbohydrates (sugar), with loss of consciousness – enter intravenously 40% dextrose (glucose), 1 – 2 mg glucagon intramuscularly. After recovery of consciousness the patient should be given foods rich in digestible carbohydrates in order to prevent recurrence of hypoglycemia.
pharmachologic effect
Pharmacological group:
Hypoglycemic agent for oral administration group II generation sulfonylureas.
Pharmacological properties:
Diabefarm® CF is an oral hypoglycemic drug, II generation sulfonylureas. It stimulates the secretion of insulin beta – pancreatic cells, enhances glucose insulinosekretornoe effect, increases the sensitivity of peripheral tissues to insulin. It stimulates the activity of intracellular enzymes – muscle glycogen. It decreases the time interval from food intake prior to the secretion of insulin. Restores the early peak of insulin secretion (as distinct from other derivatives of sulfonylureas, which affect mainly during the second stage of secretion).
Reduce postprandial glucose increase.
Besides effects on carbohydrate metabolism, improve microcirculation: decreases platelet adhesion and aggregation, normalizes vascular permeability, prevents the development of atherosclerosis and mikrotrombozov, restores the physiological process of membrane fibrinolysis. It reduces sensitivity to adrenalin receptors vessels. Slows the progression of diabetic retinopathy in the nonproliferative stage. In diabetic nephropathy amid prolonged use causes a significant reduction in the severity of proteinuria. It does not increase body weight, as has predominant effects on early peak of insulin secretion and causes hyperinsulinemia; It helps to reduce body weight in obese patients, subject to an appropriate diet.
Pharmacokinetics:
Almost completely absorbed from the gastrointestinal (GI) tract following ingestion. The concentration of active substance in the plasma increases gradually, reaching a maximum at 6-12 hours after ingestion. Food intake does not affect absorption. Communication with the plasma proteins is approximately 95%.
It is metabolized in the liver to inactive metabolites. The half-life is about 16 hours. The deduced mainly by kidneys in the form of metabolites and about 1% of the drug is excreted by the kidneys unchanged. In the elderly has not been any significant changes in clinical pharmacokinetics.
Due to the peculiarities of the dosage form, daily administration of a single dose of the drug provides an effective therapeutic concentration of gliclazide in plasma over 24 hours.
Conditions of supply of pharmacies
On prescription.
side effects
Hypoglycaemia (in violation of the dosing and inadequate diet): headache, fatigue, hunger, sweating, severe weakness, aggression, anxiety, irritability, inattention, inability to concentrate and slow reaction, depression, blurred vision, aphasia, tremor, a sense of helplessness , sensory disturbances, dizziness, loss of self-control, delirium, convulsions, hypersomnia, fainting, shallow breathing, bradycardia.
On the part of the digestive organ system: dyspepsia (nausea, diarrhea, feeling of heaviness in the epigastric); anorexia – the severity reduced when taking in a meal time; abnormal liver function (cholestatic jaundice, increased activity of “liver” transaminases).
Violations of blood: anemia, thrombocytopenia, leukopenia.
Allergic reactions: itching, rash, maculo-papular rash.
special instructions
Diabefarmom® CF treatment is carried out in conjunction with a low calorie diet low in carbohydrates. Should regularly monitor blood glucose fasting and after eating.
In the case of surgical interventions or decompensated diabetes must take into account the possibility of insulin preparations.
Must notify patients of increased risk of hypoglycemia in the case of reception of ethanol, nonsteroidal anti-inflammatory drugs and starvation. In the case of reception of ethanol may also develop disulfiramopodobnyh syndrome (abdominal pain, nausea, vomiting, headache).
Requires correction dose when physical or emotional strain, a change of diet.
Particularly sensitive to hypoglycemic drugs the elderly; Patients who are not receiving a balanced diet; weakened patients; patients with pituitary-adrenal insufficiency.
At the beginning of treatment, during adjustment of the dosage to patients prone to hypoglycemia, it is not recommended to engage in activities requiring increased attention and psychomotor speed reactions.
Storage conditions
List B. In dry, the dark m.
Dosing and Administration
Dose should be individualized depending on the clinical manifestations of the disease, fasting glucose and after 2 hours after eating. Typically, the initial daily dose (including elderly people of 65 years) is 30 mg (1 tablet), subsequently if necessary the dose is increased at intervals of at least 2 weeks.
The maximum daily dose – 120 mg (4 tablets). The drug is taken orally 1 time per day in the morning, during breakfast.
Diabefarm® Diabefarm CF may be replaced in doses from 1 to 4 tablets per day.
It may be used in combination with other hypoglycemic agents: biguanides, alpha-glucosidase inhibitor or insulin.
Patients with impaired renal function mild to moderate severity (creatinine clearance of 15 to 80 ml / min.) Drug administered in the same doses.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Farmakor PRODUCTION

There are no reviews yet.

Add your review